Sigyn Therapeutics, Inc. Sigyn Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Sigyn Therapy
  • Therapeutic Opportunities
    • Overview
    • Sepsis
    • Community Acquired Pneumonia
    • Emerging Pandemic Threats
    • ESRD Inflammation and Endotoxemia
  • News
    • Press Releases
    • Presentations
    • Resources
  • Media
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Email Alerts
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • CEO Notes

Media

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology
Oct 4, 2022

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Sigyn Therapeutics Names Hepatology Leader Dr. Donald Hillebrand to SAB
Apr 26, 2022

Sigyn Therapeutics Names Hepatology Leader Dr. Donald Hillebrand to SAB

New Sigyn CFO Maps Nasdaq Uplist, Shelf Registration Strategy
Apr 7, 2022

New Sigyn CFO Maps Nasdaq Uplist, Shelf Registration Strategy

Sigyn Therapeutics Names Neurology Leader Dr. Ajay Verma to SAB
Mar 31, 2022

Sigyn Therapeutics Names Neurology Leader Dr. Ajay Verma to SAB

Cytokine Storm: The Unmet Need Sigyn Hopes To Address
Mar 30, 2022

Cytokine Storm: The Unmet Need Sigyn Hopes To Address

Sigyn Therapeutics Names Leading Nephrologist Dr. H. David Humes to SAB
Mar 15, 2022

Sigyn Therapeutics Names Leading Nephrologist Dr. H. David Humes to SAB

Sigyn Appoints Internationally Recognized Nephrologist Dr. Alexander Yevzlin to SAB
Mar 9, 2022

Sigyn Appoints Internationally Recognized Nephrologist Dr. Alexander Yevzlin to SAB

BioTech IQ:Treatments that can reach beyond on the function of drugs? James Joyce, CEO - Sigyn Therapeutics
Feb 25, 2022

BioTech IQ:Treatments that can reach beyond on the function of drugs? James Joyce, CEO - Sigyn Therapeutics

Biotech Tuesdays: Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated
Feb 23, 2022

Biotech Tuesdays: Sigyn Therapeutics completes animal studies; Sigyn Therapy safe and well tolerated

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy
Feb 15, 2022

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

RSS
  • 1
  • 2
  • 3
  • Next
© 2023 Sigyn Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap